199 related articles for article (PubMed ID: 19797944)
1. Primary prevention of cardiovascular complications in type II diabetes patients using aspirin: a complicated tale.
Schmidt BM; Arora R
Am J Ther; 2013; 20(3):275-8. PubMed ID: 19797944
[TBL] [Abstract][Full Text] [Related]
2. Role of aspirin in the primary prevention of cardiovascular disease in diabetes mellitus: a meta-analysis.
Younis N; Williams S; Ammori B; Soran H
Expert Opin Pharmacother; 2010 Jun; 11(9):1459-66. PubMed ID: 20429671
[TBL] [Abstract][Full Text] [Related]
3. Aspirin for primary prevention of cardiovascular events in patients with diabetes: A meta-analysis.
Zhang C; Sun A; Zhang P; Wu C; Zhang S; Fu M; Wang K; Zou Y; Ge J
Diabetes Res Clin Pract; 2010 Feb; 87(2):211-8. PubMed ID: 19853947
[TBL] [Abstract][Full Text] [Related]
4. Use of antiplatelet therapy in a diabetic outpatient service of a large urban public hospital.
Bruno A; Grassi G; Dani F; Degiovanni M; Maghenzani G; Pagano G
Nutr Metab Cardiovasc Dis; 2005 Feb; 15(1):42-6. PubMed ID: 15871850
[TBL] [Abstract][Full Text] [Related]
5. Aspirin for primary prevention of cardiovascular events in people with diabetes.
Pignone M; Alberts MJ; Colwell JA; Cushman M; Inzucchi SE; Mukherjee D; Rosenson RS; Williams CD; Wilson PW; Kirkman MS; ; ;
J Am Coll Cardiol; 2010 Jun; 55(25):2878-86. PubMed ID: 20579547
[No Abstract] [Full Text] [Related]
6. [Italian intersocietary consensus document on aspirin therapy in primary cardiovascular prevention].
Volpe M; Abrignani MG; Borghi C; Coccheri S; Gresele P; Patti G; Trimarco B; De Caterina R
G Ital Cardiol (Rome); 2014; 15(7-8):442-51. PubMed ID: 25174598
[TBL] [Abstract][Full Text] [Related]
7. Changing aspirin use in patients with Type 2 diabetes in the UKPDS.
Cull CA; Neil HA; Holman RR
Diabet Med; 2004 Dec; 21(12):1368-71. PubMed ID: 15569143
[TBL] [Abstract][Full Text] [Related]
8. Update on aspirin in the treatment and prevention of cardiovascular disease.
Hennekens CH
Am J Manag Care; 2002 Dec; 8(22 Suppl):S691-700. PubMed ID: 12512736
[TBL] [Abstract][Full Text] [Related]
9. Review of an article: aspirin for primary prevention of cardiovascular events in people with diabetes. A position statement of the American Diabetes Association (ADA), a scientific statement of the American Heart Association(AHA), and an expert consensus document of the American College of Cardiology Foundation (ACCF). Diabetes Care, 33:6; June 2010; 1395-1402.
Gilpin VL; ; ;
J Vasc Nurs; 2010 Dec; 28(4):154-5. PubMed ID: 21074118
[No Abstract] [Full Text] [Related]
10. [Should we treat all diabetic patients with aspirin in primary prevention?].
Righetti A; De Moerloose P; Philippe J
Rev Med Suisse; 2005 Jun; 1(22):1500-4. PubMed ID: 16025889
[TBL] [Abstract][Full Text] [Related]
11. The benefit of aspirin therapy in type 2 diabetes: what is the evidence?
Sirois C; Poirier P; Moisan J; Grégoire JP
Int J Cardiol; 2008 Sep; 129(2):172-9. PubMed ID: 18495263
[TBL] [Abstract][Full Text] [Related]
12. Review of guidelines on primary prevention of cardiovascular disease with aspirin: how much evidence is needed to turn a tanker?
Matthys F; De Backer T; De Backer G; Stichele RV
Eur J Prev Cardiol; 2014 Mar; 21(3):354-65. PubMed ID: 23610452
[TBL] [Abstract][Full Text] [Related]
13. Effects of rosiglitazone and aspirin on experimental model of induced type 2 diabetes in rats: focus on insulin resistance and inflammatory markers.
Abdin AA; Baalash AA; Hamooda HE
J Diabetes Complications; 2010; 24(3):168-78. PubMed ID: 19328014
[TBL] [Abstract][Full Text] [Related]
14. [Aspirin in primary prevention of cardiovascular diseases: how to balance risks and benefits].
De Caterina R; Orlando D; Berti V; Coccheri S
G Ital Cardiol (Rome); 2012; 13(7-8):494-502. PubMed ID: 22781376
[TBL] [Abstract][Full Text] [Related]
15. Application of U.S. guidelines in other countries: aspirin for the primary prevention of cardiovascular events in Japan.
Morimoto T; Fukui T; Lee TH; Matsui K
Am J Med; 2004 Oct; 117(7):459-68. PubMed ID: 15464702
[TBL] [Abstract][Full Text] [Related]
16. Prevention of cardiovascular disease in type-2 diabetes: how to improve the clinical efficacy of aspirin.
Evangelista V; Totani L; Rotondo S; Lorenzet R; Tognoni G; De Berardis G; Nicolucci A
Thromb Haemost; 2005 Jan; 93(1):8-16. PubMed ID: 15630484
[TBL] [Abstract][Full Text] [Related]
17. [Acetylsalicylic acid does not prevent cardiovascular diseases in diabetic patients].
Kramer MH
Ned Tijdschr Geneeskd; 2009 Feb; 153(7):291. PubMed ID: 19291945
[No Abstract] [Full Text] [Related]
18. Aspirin in the primary prevention of cardiovascular disease in diabetes mellitus: A new perspective.
Rocca B; Patrono C
Diabetes Res Clin Pract; 2020 Feb; 160():108008. PubMed ID: 31926190
[TBL] [Abstract][Full Text] [Related]
19. [Aspirin as primary prevention for diabetic patients].
Fumeaux D; Becerra ME; Philippe J; Louis-Simonet M
Rev Med Suisse; 2010 Feb; 6(234):244-8. PubMed ID: 20334083
[TBL] [Abstract][Full Text] [Related]
20. [Acetylsalicylic acid in patients with diabetes mellitus: can be used for secondary but not primary prevention of cardiovascular events].
Klomp CM; ten Cate H; Stehouwer CD; Schaper NC
Ned Tijdschr Geneeskd; 2009; 153():A109. PubMed ID: 19785798
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
